This program addresses atherosclerotic cardiovascular disease (ASCVD), a leading cause of death worldwide, and hypercholesterolemia as a major modifiable risk factor, despite suboptimal lipid testing rates and up to 30% of patients showing statin intolerance. This program covers guideline-directed LDL-C screening strategies alongside efficacy and safety data on newer lipid-lowering therapies, including bempedoic acid, PCSK9 inhibitors, and a CETP inhibitor. This program equips PCPs and allied HCPs to navigate adherence challenges, disparities, and comorbidities while developing individualized care plans for patients with hyperlipidemia and other CV risk factors.
